---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-26-000204"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-05-13T20:03:13+00:00"
generated_at: "2026-05-13T22:18:21.632578+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vertex shareholders approve 2026 Stock Plan, all director nominees, and shareholder written consent proposal

## Summary
- All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.
- Shareholders ratified Ernst & Young as independent auditor for 2026 (223.5M for).
- Advisory say-on-pay passed with 207.9M votes for vs. 14.5M against.
- 2026 Stock and Option Plan approved (216.1M for, 6.5M against), replacing 2013 plan.
- Shareholder proposal for right to act by written consent passed (126.9M for vs. 95.8M against).

## SEC filing metadata
- accession: 0000875320-26-000204
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-05-13T20:03:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/0000875320-26-000204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/vrtx-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-26-000204
- JSON: https://secwatch.observer/filing/0000875320-26-000204.json
- Plain text: https://secwatch.observer/filing/0000875320-26-000204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.